



www.G2Gconsulting.com

Government Bioscience Grant (GBG) Report
March 2017

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Eligibility	Link
			BROAD AGENCY ANNOUNCEMENTS				
1.	U.S. Naval Research Laboratory (NRL) BAA	N00173-17-S-BA01	This is NRL's BAA. Proposals may range from theoretical studies to proof-of-concept to include fabrication and delivery of a prototype. However, this is limited to research procurements for which it would be impossible to draft an adequate RFP in sufficient detail without restraining the technical response and thus hindering competition rather than expanding it. BAA topics range from remote sensing and imaging to the effects of radiation, to a range of IT topics, none of which are exclusively medical in nature.	White Papers are accepted on a rolling basis, no hard deadline	Dependent upon proposal	Unrestricted	https://www.nrl.navy.mil/doing-business/contracting-division/baa/current
			CANCER				
2.	Research Answers to NCI's Provocative Questions (PQs) (R01) (NIH)	RFA-CA-17-017	The purpose of this FOA is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.	Letter of Intent Due: 5/28/17 Full Proposal Due: 6/28/17	Dependent upon proposal, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-017.html

3.	Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01) (NIH)	PAR-17-093	The purpose of this FOA is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. A distinguishing feature of each application will be formation of an academic-industrial partnership. The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.	Full Proposal Due: 6/7/17	Dependent upon proposal, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-093.html
4.	Inter-organelle Communication in Cancer (R01) (NIH)	PAR-17-203	The purpose of this FOA is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity. This emerging area promotes the concept that organelle networks coordinate oncogenic or tumor suppressive pressures that influence cell behaviors.	Letter of Intent Due: 7/16/17 Full Proposal Due: 8/16/17	Dependent upon proposal, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-203.html
5.	Alliance of Glycobiologists for Cancer Research: Translational Tumor Glycomics Laboratories (U01) (NIH)	PAR-17-206	The purpose of this FOA is to continue support for the program referred to as the Alliance of Glycobiologists for Cancer Research. NCI encourages research projects to elucidate how changes in cellular carbohydrates may promote cancer initiation and progression and use this information to identify glycan-based abnormalities to serve as biomarkers for early cancer detection or risk assessment. These changes may be studied at the level of glycoproteins, glycolipids, glycosaminoglycans, and/or their binding proteins. It is expected that the most promising biomarker candidates will ultimately be tested in clinical validation studies, although such validation studies are not required for the proposed projects.	Letter of Intent Due: 5/8/17 Full Proposal Due: 6/8/17	Up to \$500,000 per year for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-206.html

6.	Mechanisms of Alcohol-associated Cancers (R01) (NIH)	PA-17-220	This FOA invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.	Letter of intent Due: 5/5/17 Full Proposal Due: 6/5/17	Dependent upon proposal, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-17-220.html
7.	Mechanisms of Alcohol-associated Cancers (R21) (NIH)	PA-17-219	This FOA invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.	Letter of intent Due: 5/5/17 Full Proposal Due: 6/5/17	Up to \$200,000 per year for a max of \$275,000, for up to 2 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-17-219.html
8.	Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33) (NIH)	RFA-CA-17-023	This FOA is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on the advanced development and rigorous validation of new enabling technologies/tools/capabilities with a transformative potential for cancer research and clinical oncology. Specifically, this FOA targets the following four areas designated as scientific priorities: Enhanced experimental and analytical capabilities addressing complexities of cancer development; New capabilities advancing precise clinical diagnosis of cancer patients; Novel predictive ex vivo and/or in silico modeling approaches; and new technologies/approaches to improve biospecimen and data quality.	Letter of intent Due: 4/10/17 Full Proposal Due: 5/10/17	Up to \$325,000 per year for up to 3 years	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-023.html

			INFECTIOUS DISEASE				
9.	Pandemic Prevention Platform (P3) (DARPA)	HR001117S0019	The goal of the Pandemic Prevention Platform (P3) program is to develop an integrated capability to deliver pandemic prevention countermeasures to humans in <60 days. The P3 program aims to revolutionize outbreak response capabilities to allow rapid discovery, characterization, production, and testing of efficacious medical countermeasures. The P3 program aims to innovate in the following areas: Generation of virus stock (including viral unknowns); Rapid evolution of antibody candidates; Gene-encoded antibody delivery methods.	Proposal Abstract Due: 3/20/17 Full Proposal Due: 5/8/17	Dependent upon agency funding	Unrestricted	https://www.fbo.gov/index?s=opportunity&mode=form&id=3474e0b1078fd a61da7d58237821dc73&tab=core&tabmode=list&=
			NANOTECHNOLOGY				
10.	Innovative Research in Cancer Nanotechnology (IRCN) (R01)	PAR-17-240	This Funding Opportunity Announcement (FOA) encourages applications for the development of innovative research projects in cancer nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. This scope includes research concerning the delivery of nanoparticles and/or nanodevices to desired and intended cancer targets <i>in vivo</i> and/or characterization of <i>in vitro</i> detection and diagnostic devices.	Full Proposal Due: 11/21/17 Open Until: 5/21/2020	Up to \$450,000 per year for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-240.html
			PAIN MANAGEMENT, PTSD, & SLEEP				
11.	NCCIH Natural Product Phase II Clinical Trial Cooperative Agreement (U01) (NIH)	PAR-17-216	This FOA invites cooperative agreement applications for investigator-initiated clinical trials of natural products to treat clinical symptoms such as those associated with sleep disturbance, pain conditions, or some mental health conditions (e.g., mild to moderate depression, anxiety, and post-traumatic stress), or examine the effects of probiotics and other natural products on gut-microbiome interactions with the brain and/or immune system. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable biological signature.	Letter of Intent Due: 6/7/17 Full Proposal Due: 7/7/17	Dependent upon proposal, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-216.html

			PEDIATRICS				
12.	Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03) (NIH)	PAR-17-188	The purpose of this FOA is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation.	Letter of Intent Due: 7/7/17 Full Proposal Due: 8/7/17	Up to \$50,000 per year for up to 2 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-188.html
13.	Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21) (NIH)	PAR-17-187	Same opportunity as above, through the R21 funding mechanism.	Same due date as above	Up to \$200,000 per year, with a max of \$275,000, for up to 2 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-187.html
14.	Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01) (NIH)	PAR-17-189	Same opportunity as above, through the traditional R01 funding mechanism.	Same due date as above	Dependent upon proposal, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-189.html
15.	Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01)	PAR-17-193	This Funding Opportunity Announcement (FOA) encourages grant applications to address different and complementary research needs for the development and acceptability of pediatric drug formulations in different age groups. Development and testing of novel pediatric drug delivery systems is also part of this initiative. Companion FOA's through other funding mechanisms include: PAR-17-191, R03 Small Grant Program PAR-17-192, R21 Exploratory/Developmental Grant PAR-17-200, R41 STTR Grant - Phase I only PAR-17-199, R43 SBIR Grant - Phase I only	Letter of Intent Due: 5/5/2017 Full Proposal Due: 6/5/2017 Open until 2020	Dependent upon proposal, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-193.html

			SUBSTANCE ABUSE				
16.	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U01) (NIH)	PAR-17-185	The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction.	Letter of Intent Due: 5/23/17 Full Proposal Due: 6/23/17	Dependent upon application request, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-17-185.html
17.	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19) (NIH)	PAR-17-186	Same opportunity as above, through U19 funding mechanism.	Letter of Intent Due: 5/23/17 Full Proposal Due: 6/23/17	Dependent upon application request, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-17-186.html
18.	Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01) (NIH)	PA-17-196	The intent of this FOA is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50.	Letter of Intent Due: 5/5/17 Full Proposal Due: 6/5/17	Dependent upon proposal, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-17-196.html

THERAPEUTICS							
19.	Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UG3/UH3) (NIH)	RFA-TR-17-003	This FOA solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases unique to pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Asset's target will have a positive impact on the disease/condition.	Letter of Intent Due: 8/15/17 Full Proposal Due: 9/15/17	Up to \$300,000 per year for UG3, up to \$500,000 for UH3 per year, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-17-003.html
SBIR/STTR							
20.	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) (NIH)	PAR-17-201	The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing.	Letter of Intent Due: 7/9/17 Full Proposal Due: 8/9/17	Phase I: Up to \$500,000 per year for up to 2 years Phase II: Up to \$1.5 million for up to 3 years	Small Businesses	https://grants.nih.gov/grants/guide/pa-files/PAR-14-292.html